<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FERRLECIT- sodium ferric gluconate complex injection </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Ferrlecit<span class="Sup">® </span>safely and effectively.  See full prescribing information for Ferrlecit. <br><br>Ferrlecit (sodium ferric gluconate complex in sucrose injection), <br>For intravenous (IV) use <br>Initial U.S. Approval: 1999</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Ferrlecit is an iron replacement product for treatment of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> in adult patients and in pediatric patients age 6 years and older with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> receiving hemodialysis who are receiving supplemental epoetin therapy. (<a href="#S1">1</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adult Patients - The recommended adult dosage is 10mL (125 mg of elemental iron) diluted in 100 mL of 0.9% sodium chloride administered by intravenous infusion over 1 hour per dialysis session or undiluted as a slow intravenous injection (at a rate of up to 12.5 mg/min) per dialysis session. (<a href="#S2.1">2.1</a>)</li>
<li>Pediatric Patients - The recommended pediatric dosage is 0.12 mL/kg (1.5 mg/kg of elemental iron) diluted in 25 mL 0.9% sodium chloride and administered by intravenous infusion over 1 hour per dialysis session. (<a href="#S2.2">2.2</a>)</li>
<li>Do not mix Ferrlecit with other medications or add to parenteral nutrition solutions for intravenous infusion. </li>
<li>Administer in 0.9% saline (<a href="#S2">2</a>).</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Ferrlecit is supplied in a single use vial containing 62.5 mg of elemental iron in 5 mL. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sodium ferric gluconate or any of its inactive components. (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:  Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> during and after Ferrlecit administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferrlecit when personnel and therapies are immediately available for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. (<a href="#S5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: Ferrlecit may cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during and following each Ferrlecit dose. (<a href="#S5.2">5.2</a>)</li>
<li>Iron  Overload: Regularly monitor hematologic responses during Ferrlecit therapy.  Do not administer Ferrlecit to patients with <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span>. (<a href="#S5.3">5.3</a>)</li>
<li>Benzyl Alcohol Toxicity:  Premature and low-birthweight infants may be more likely to develop toxicity. (<a href="#S5.4">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions (≥10%) in adult patients were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In patients 6 to 15 years of age the most common adverse reactions (≥10%) were <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy:  Use only if clearly needed (contains benzyl alcohol). (<a href="#S8.1">8.1</a>)</li>
<li>Nursing Mothers:  Caution should be exercised when administered to a nursing woman (contains benzyl alcohol). (<a href="#S8.3">8.3</a>)</li>
<li>Pediatric Use:  Safety and effectiveness have not been established in pediatric patients &lt;6 years of age. (<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Adult Dosage and Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Pediatric Dosage and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Iron Overload</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Benzyl Alcohol Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 	Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Ferrlecit is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> in adult patients and in pediatric patients age 6 years and older with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> receiving hemodialysis who are receiving supplemental epoetin therapy.  </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dosage of Ferrlecit is expressed in terms of mg of elemental iron. Each 5 mL sterile, single-use vial contains 62.5 mg of elemental iron (12.5 mg/mL). </p>
<p>Do not mix Ferrlecit with other medications, or add to parenteral nutrition solutions for intravenous infusion. The compatibility of Ferrlecit with intravenous infusion vehicles other than 0.9% sodium chloride has not been evaluated. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever the solution and container permit. If diluted, use immediately.  </p>
<p>Ferrlecit treatment may be repeated if <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> reoccurs.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Adult Dosage and Administration</h2>
<p class="First">The recommended dosage of Ferrlecit for the repletion treatment of <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> in hemodialysis patients is 10 mL of Ferrlecit (125 mg of elemental iron). Ferrlecit may be diluted in 100 mL of 0.9% sodium chloride administered by intravenous infusion over 1 hour per dialysis session. Ferrlecit may also be administered undiluted as a slow intravenous injection (at a rate of up to 12.5 mg/min) per dialysis session. For repletion treatment most patients may require a cumulative dose of 1000 mg of elemental iron administered over 8 dialysis sessions. Ferrlecit has been administered at sequential dialysis sessions by infusion or by slow intravenous injection during the dialysis session itself. </p>
<p>Data from Ferrlecit postmarketing spontaneous reports indicate that individual doses exceeding 125 mg may be associated with a higher incidence and/or severity of adverse events [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Pediatric Dosage and Administration</h2>
<p class="First">The recommended pediatric dosage of Ferrlecit for the repletion treatment of <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> in hemodialysis patients is 0.12 mL/kg Ferrlecit (1.5 mg/kg of elemental iron) diluted in 25 mL 0.9% sodium chloride and administered by intravenous infusion over 1 hour per dialysis session. The maximum dosage should not exceed 125 mg per dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Ferrlecit is available as a single use vial, containing 62.5 mg of elemental iron in 5 mL volume.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sodium ferric gluconate or any of its components.</li></ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferrlecit in post marketing experience.  Patients may present with <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, or collapse.  Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> during and after Ferrlecit administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferrlecit when personnel and therapies are immediately available for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> [see <span class="Italics"><a href="#S6">Adverse Reactions (6)</a></span>].  </span></p>
<p>In the single-dose, post-marketing, safety study one patient experienced a life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, severe lower <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> for 20 minutes) following Ferrlecit administration. Among 1,097 patients who received Ferrlecit in this study, there were 9 patients (0.8%) who had an adverse reaction that, in the view of the investigator, precluded further Ferrlecit administration. These included one life-threatening reaction, six <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> x2, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>/<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>), and two other reactions (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>). Another 2 patients experienced (0.2%) <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> not deemed to represent <span class="product-label-link" type="condition" conceptid="4240582" conceptname="Drug intolerance">drug intolerance</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) following Ferrlecit administration. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </h2>
<p class="First">Ferrlecit may cause clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest, back, flanks, or groin has been reported. These hypotensive reactions may or may not be associated with signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and usually resolve within one to two hours. In the single dose safety study, post-administration hypotensive events were observed in 22/1,097 patients (2%) following Ferrlecit administration. Transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur during dialysis.  Administration of Ferrlecit may augment <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> caused by dialysis. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during and following Ferrlecit administration [see <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">Iron Overload</span> </h2>
<p class="First">Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic <span class="product-label-link" type="condition" conceptid="4305596" conceptname="Hemosiderosis">hemosiderosis</span>. Patients receiving Ferrlecit require periodic monitoring of hematologic and iron parameters (hemoglobin, hematocrit, serum ferritin, and <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Benzyl Alcohol Toxicity</h2>
<p class="First">Ferrlecit contains benzyl alcohol as a preservative.  Benzyl alcohol has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients.  The minimum amount of benzyl alcohol at which toxicity may occur is not known.  Premature and low-birth weight infants may be more likely to develop toxicity <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> [see <span class="Italics"><a href="#S4">Contraindications (4)</a></span> and <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>The most commonly reported adverse reactions (≥10%)  in adult patients were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, abnormal erythrocytes (e.g., changes in morphology, color, or number of red blood cells), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In patients 6 to 15 years of age the most common adverse reactions (≥10%) were <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Studies A and B</span></p>
<p>In multiple dose Studies A and B (total 126 adult patients), the most frequent treatment emergent adverse reactions following Ferrlecit were: </p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span> (33%), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (10%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (10%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (7%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (6%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (5%), <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, carcinoma, flu-like syndrome, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. </p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> (25%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (13%), <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> (6%), <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, decreased level of consciousness.</p>
<p><span class="Bold">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (11%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> (6%), <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span> (6%), <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. </p>
<p><span class="Bold">Cardiovascular System:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (29%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (13%), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (6%), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (5%), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. </p>
<p><span class="Bold">Gastrointestinal System:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (35%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (6%), <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>.</p>
<p><span class="Bold">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> (10%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, arm <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (6%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p><span class="Bold">Genitourinary System:</span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and menorrahagia.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, rolling of the eyes, watery eyes, puffy eye lids, <span class="product-label-link" type="condition" conceptid="4009186" conceptname="Arcus senilis">arcus senilis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the eye, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>.</p>
<p><span class="Bold">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (6%), <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span> (5%), <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. </p>
<p><span class="Bold">Hematologic System:</span> abnormal erythrocytes (11%) (changes in morphology, color, or number of red blood cells), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Study C – Pediatric</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2.1"></a><p></p>
<p class="First"><span class="Bold">Pediatric Patients:</span> In a clinical trial of 66 iron-deficient pediatric hemodialysis patients, 6 to 15 years of age, inclusive, who were receiving a stable erythropoietin dosing regimen, the most common adverse reactions, occurring in ≥5%, regardless of treatment dosage, were: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (35%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (24%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (23%), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (17%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (11%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (9%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (9%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (9%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (9%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (8%), <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (6%), and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (6%). More patients in the higher dose group (3.0 mg/kg) than in the lower dose group (1.5 mg/kg) experienced the following adverse events: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (41% vs. 28%), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (21% vs. 13%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (15% vs. 3%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (29% vs. 19%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (15% vs. 3%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (12% vs. 6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (12% vs. 9%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (12% vs. 6%), and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (9% vs. 3%).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 	Post Marketing Experience</h2>
<p class="First">In the single-dose, postmarketing safety study, 11% of patients who received Ferrlecit and 9.4% of patients who received placebo reported adverse reactions. The most frequent adverse reactions following Ferrlecit were: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (2%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (0.7%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (0.6%), <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (0.5%), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (0.5%), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (0.5%), and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (0.4%). The following additional events were reported in two or more patients: <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>In the multiple-dose, open-label surveillance study, 28% of the patients received concomitant angiotensin converting enzyme inhibitor (ACEi) therapy. The incidences of both <span class="product-label-link" type="condition" conceptid="4240582" conceptname="Drug intolerance">drug intolerance</span> or suspected allergic events following first dose Ferrlecit administration were 1.6% in patients with concomitant ACEi use compared to 0.7% in patients without concomitant ACEi use. The patient with a life-threatening event was not on ACEi therapy. One patient had <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> immediately on Ferrlecit exposure. No <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred and the event resolved rapidly and spontaneously without intervention other than drug withdrawal.  </p>
<p>The following additional adverse reactions have been identified with the use of Ferrlecit from postmarketing spontaneous reports: anaphylactic-type reactions, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.</p>
<p>Individual doses exceeding 125 mg may be associated with a higher incidence and/or severity of adverse events based on information from postmarketing spontaneous reports. These adverse events included <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and <span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">peripheral swelling</span>. </p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Drug-drug interactions involving Ferrlecit have not been studied. Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category B</p>
<p>There are no adequate and well-controlled studies with Ferrlecit in pregnant women. Reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m<span class="Sup">2</span>/day) and in rats at up to 20 mg/kg/day (120 mg/m<span class="Sup">2</span>/day).  The doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m<span class="Sup">2</span>/day) on a body surface area basis and have revealed no evidence of harm to the fetus due to Ferrlecit. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Ferrlecit contains benzyl alcohol as a preservative.  There are no known adverse outcomes associated with fetal exposure to the preservative benzyl alcohol through maternal drug administration; however, the preservative benzyl alcohol can cause serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when administered intravenously to neonates and infants <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Ferrlecit is excreted in human milk. Benzyl alcohol present in maternal serum is likely to cross into human milk and may be orally absorbed by a nursing infant. Caution should be exercised when Ferrlecit is administered to a nursing woman [see <span class="Italics"><a href="#S8.4">Use in Specific Populations (8.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Ferrlecit have been established in pediatric patients 6 to 15 years of age <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>, and <a href="#S14">Clinical Studies (14)</a></span>. Safety and effectiveness in pediatric patients younger than 6 years of age have not been established. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Underline">Benzyl Alcohol Toxicity and Pediatrics</span></p>
<p>The preservative benzyl alcohol has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients.  The "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome" (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages &gt;99 mg/kg/day in neonates and low-birth weight infants. Additional symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. </p>
<p>Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources. </p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Ferrlecit did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The Ferrlecit iron complex is not dialyzable. </p>
<p>No data is available regarding <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of Ferrlecit in humans. Excessive dosages of Ferrlecit may lead to accumulation of iron in storage sites potentially leading to <span class="product-label-link" type="condition" conceptid="4305596" conceptname="Hemosiderosis">hemosiderosis</span>.  Do not administer Ferrlecit to patients with <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> [see <span class="Italics"><a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
<p>Individual doses exceeding 125 mg may be associated with a higher incidence and/or severity of adverse events [see <span class="Italics"><a href="#S6.2">Post Marketing Experiences (6.2)</a></span>].</p>
<p>Ferrlecit at elemental iron doses of 125 mg/kg, 78.8 mg/kg, 62.5 mg/kg and 250 mg/kg caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in mice, rats, rabbits, and dogs respectively. The major symptoms of acute toxicity were <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">staggering</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, increases in the <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Ferrlecit<span class="Sup">® </span>(sodium ferric gluconate complex in sucrose injection), an iron replacement product, is a stable macromolecular complex with an apparent molecular weight on gel chromatography of 289,000 – 440,000 daltons. The macromolecular complex is negatively charged at alkaline pH and is present in solution with sodium cations. The product has a deep red color indicative of ferric oxide linkages. The chemical name is D-Gluconic acid, iron (3+) sodium salt.</p>
<p>The structural formula is considered to be [NaFe<span class="Sub">2</span>O<span class="Sub">3</span>(C<span class="Sub">6</span>H<span class="Sub">11</span>O<span class="Sub">7</span>)(C<span class="Sub">12</span>H<span class="Sub">22</span>0<span class="Sub">11</span>)5]<span class="Sub">n≈200∙</span></p>
<p>Each sterile, single-use vial of 5 mL of Ferrlecit for intravenous injection contains 62.5 mg (12.5 mg/mL) of elemental iron as the sodium salt of a ferric ion carbohydrate complex in an alkaline aqueous solution with approximately 20% sucrose w/v (195 mg/mL) in water for injection, pH 7.7 – 9.7. </p>
<p>Each mL contains 9 mg of benzyl alcohol as an inactive ingredient.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Ferrlecit is used to replete the body content of iron. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport. Additionally, iron is necessary for metabolism and various enzymatic processes. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Multiple sequential single dose intravenous pharmacokinetic studies were performed on 14 healthy iron-deficient volunteers. Entry criteria included hemoglobin ≥10.5 gm/dL and <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> ≤15% (TSAT) or serum ferritin value ≤20 ng/mL. In the first stage, each subject was randomized 1:1 to undiluted Ferrlecit injection of either 125 mg/hr or 62.5 mg/0.5 hr (2.1 mg/min). Five days after the first stage, each subject was re-randomized 1:1 to undiluted Ferrlecit injection of either 125 mg/7 min or 62.5 mg/4 min (&gt;15.5 mg/min). </p>
<p>Peak drug levels (C<span class="Sub">max</span>) varied significantly by dosage and by rate of administration with the highest C<span class="Sub">max </span>observed in the regimen in which 125 mg was administered in 7 minutes (19.0 mg/L). The terminal elimination half-life for drug bound iron was approximately 1 hour. Half-life varied by dose but not by rate of administration. Half-life values were 0.85 and 1.45 hours for the 62.5 mg/4 min and 125 mg/7 min regimens, respectively. Total clearance of Ferrlecit was 3.02 to 5.35 L/h. The AUC for Ferrlecit bound iron varied by dose from 17.5 mg-h/L (62.5 mg) to 35.6 mg-h/L (125 mg). Approximately 80% of drug bound iron was delivered to transferrin as a mononuclear ionic iron species within 24 hours of administration in each dosage regimen. Direct movement of iron from Ferrlecit to transferrin was not observed. Mean peak <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> returned to near baseline by 40 hours after administration of each dosage regimen.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Pediatrics: </span>Single dose intravenous pharmacokinetic analyses were performed on 48 iron-deficient pediatric hemodialysis patients. Twenty-two patients received 1.5 mg/kg Ferrlecit and 26 patients received 3.0 mg/kg Ferrlecit (maximum dose 125 mg). The mean C<span class="Sub">max</span>, AUC<span class="Sub">0–∞</span>, and terminal elimination half-life values following a 1.5 mg/kg dose were 12.9 mg/L, 95.0 mg∙hr/L, and 2.0 hours, respectively. The mean C<span class="Sub">max</span>, AUC<span class="Sub">0–∞</span> , and terminal elimination half-life values following a 3.0 mg/kg dose were 22.8 mg/L, 170.9 mg∙hr/L, and 2.5 hours, respectively.</p>
<p><span class="Italics">In vitro</span> experiments have shown that less than 1% of the iron species within Ferrlecit can be dialyzed through membranes with pore sizes corresponding to 12,000 to 14,000 daltons over a period of up to 270 minutes. Human studies in renally competent patients suggest the clinical insignificance of urinary excretion.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term carcinogenicity studies of sodium ferric gluconate in animals were not performed. </p>
<p>Sodium ferric gluconate was not genotoxic in the Ames test or the rat micronucleus test. Sodium ferric gluconate produced a clastogenic effect in an <span class="Italics">in vitro</span> chromosomal aberration assay in Chinese hamster ovary cells. </p>
<p>Studies to assess the effects of sodium ferric gluconate on fertility were not conducted. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Two clinical studies (Studies A and B) were conducted in adults and one clinical study was conducted in pediatric patients (Study C) to assess the efficacy and safety of Ferrlecit.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Study A</span></p>
<p>Study A was a three-center, randomized, open-label study of the safety and efficacy of two doses of Ferrlecit administered intravenously to iron-deficient hemodialysis patients. The study included both a dose-response concurrent control and an historical control. Enrolled patients received a test dose of Ferrlecit (25 mg of elemental iron) and were then randomly assigned to receive Ferrlecit at cumulative doses of either 500 mg (low dose) or 1000 mg (high dose) of elemental iron. Ferrlecit was given to both dose groups in eight divided doses during sequential dialysis sessions (a period of 16 to 17 days). At each dialysis session, patients in the low-dose group received Ferrlecit 62.5 mg of elemental iron over 30 minutes, and those in the high-dose group received Ferrlecit 125 mg of elemental iron over 60 minutes. The primary endpoint was the change in hemoglobin from baseline to the last available observation through Day 40. </p>
<p>Eligibility for this study included chronic hemodialysis patients with a hemoglobin below 10 g/dL (or hematocrit at or below 32%) and either serum ferritin below 100 ng/mL or <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> below 18%. Exclusion criteria included significant underlying disease or inflammatory conditions or an epoetin requirement of greater than 10,000 units three times per week. Parenteral iron and red cell transfusion were not allowed for two months before the study. Oral iron and red cell transfusion were not allowed during the study for Ferrlecit-treated patients. </p>
<p>The historical control population consisted of 25 chronic hemodialysis patients who received only oral iron supplementation for 14 months and did not receive red cell transfusion. All patients had stable epoetin doses and hematocrit values for at least two months before initiation of oral iron therapy. </p>
<p>The evaluated population consisted of 39 patients in the low-dose Ferrlecit (sodium ferric gluconate complex in sucrose injection) group (50% female, 50% male; 74% white, 18% black, 5% Hispanic, 3% Asian; mean age 54 years, range 22–83 years), 44 patients in the high-dose Ferrlecit group (50% female, 48% male, 2% unknown; 75% white, 11% black, 5% Hispanic, 7% other, 2% unknown; mean age 56 years, range 20–87 years), and 25 historical control patients (68% female, 32% male; 40% white, 32% black, 20% Hispanic, 4% Asian, 4% unknown; mean age 52 years, range 25–84 years). </p>
<p>The mean baseline hemoglobin and hematocrit were similar between treatment and historical control patients: 9.8 g/dL and 29% and 9.6 g/dL and 29% in low- and high-dose Ferrlecit-treated patients, respectively, and 9.4 g/dL and 29% in historical control patients. Baseline serum <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> was 20% in the low-dose group, 16% in the high-dose group, and 14% in the historical control. Baseline serum ferritin was 106 ng/mL in the low-dose group, 88 ng/mL in the high-dose group, and 606 ng/mL in the historical control. </p>
<p>Patients in the high-dose Ferrlecit group achieved significantly higher increases in hemoglobin and hematocrit than patients in the low-dose Ferrlecit group.    See <a href="#table1">Table 1</a>.</p>
<a name="table1"></a><table width="100%">
<caption><span>TABLE 1 Study A: Hemoglobin, Hematocrit, and Iron Studies</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left" colspan="3">Mean Change from Baseline to Two Weeks After Cessation of Therapy</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule Toprule" align="center">Ferrlecit 1000 mg IV<br> (N=44)</th>
<th class="Rrule Toprule" align="center">Ferrlecit 500 mg IV<br> (N=39)</th>
<th class="Rrule Toprule" align="center">Historical Control Oral Iron<br> (N=25)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>p&lt;0.01 versus the 500 mg group.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Hemoglobin (g/dL)</td>
<td class="Rrule" align="center">1.1<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">0.3</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hematocrit (%)</td>
<td class="Rrule" align="center">3.6<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">1.4</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">Transferrin Saturation</span> (%)</td>
<td class="Rrule" align="center">8.5</td>
<td class="Rrule" align="center">2.8</td>
<td class="Rrule" align="center">6.1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Serum Ferritin (ng/mL)</td>
<td class="Rrule" align="center">199</td>
<td class="Rrule" align="center">132</td>
<td class="Rrule" align="center">NA</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold">Study B</span></p>
<p>Study B was a single-center, non-randomized, open-label, historically-controlled, study of the safety and efficacy of variable, cumulative doses of intravenous Ferrlecit in iron-deficient hemodialysis patients. Ferrlecit administration was identical to Study A. The primary efficacy variable was the change in hemoglobin from baseline to the last available observation through Day 50. </p>
<p>Inclusion and exclusion criteria were identical to those of Study A as was the historical control population. Sixty-three patients were evaluated in this study: 38 in the Ferrlecit-treated group (37% female, 63% male; 95% white, 5% Asian; mean age 56 years, range 22– 84 years) and 25 in the historical control group (68% female, 32% male; 40% white, 32% black, 20% Hispanic, 4% Asian, 4% unknown; mean age 52 years, range 25–84 years). </p>
<p>Ferrlecit-treated patients were considered to have completed the study per protocol if they received at least eight Ferrlecit doses of either 62.5 mg or 125 mg of elemental iron. A total of 14 patients (37%) completed the study per protocol. Twelve (32%) Ferrlecit-treated patients received less than eight doses, and 12 (32%) patients had incomplete information on the sequence of dosing. Not all patients received Ferrlecit at consecutive dialysis sessions and many received oral iron during the study. </p>
<table width="100%">
<col align="left" valign="top" width="19%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Cumulative Ferrlecit Dose (mg of elemental iron)</td>
<td class="Rrule" align="left">62.5</td>
<td class="Rrule" align="left">250</td>
<td class="Rrule" align="left">375</td>
<td class="Rrule" align="left">562.5</td>
<td class="Rrule" align="left">625</td>
<td class="Rrule" align="left">750</td>
<td class="Rrule" align="left">1000</td>
<td class="Rrule" align="left">1125</td>
<td class="Rrule" align="left">1187.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Patients (#)</td>
<td class="Rrule" align="left">1</td>
<td class="Rrule" align="left">1</td>
<td class="Rrule" align="left">2</td>
<td class="Rrule" align="left">1</td>
<td class="Rrule" align="left">10</td>
<td class="Rrule" align="left">4</td>
<td class="Rrule" align="left">12</td>
<td class="Rrule" align="left">6</td>
<td class="Rrule" align="left">1</td>
</tr>
</tbody>
</table>
<p>Baseline hemoglobin and hematocrit values were similar between the treatment and control groups, and were 9.1 g/dL and 27.3%, respectively, for Ferrlecit-treated patients. Serum iron studies were also similar between treatment and control groups, with the exception of serum ferritin, which was 606 ng/mL for historical control patients, compared to 77 ng/mL for Ferrlecit-treated patients. </p>
<p>In this patient population, only the Ferrlecit-treated group achieved increase in hemoglobin and hematocrit from baseline. See <a href="#table2">Table 2</a>. </p>
<a name="table2"></a><table width="100%">
<caption><span>TABLE 2 Study B: Hemoglobin, Hematocrit, and Iron Studies</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="3">Mean Change from Baseline to One Month After Treatment</th></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Ferrlecit (N=38)</th>
<th class="Rrule" align="center">Oral Iron (N=25)</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">change</th>
<th class="Rrule" align="center">change</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Hemoglobin (g/dL)</td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hematocrit (%)</td>
<td class="Rrule" align="center">3.8</td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">Transferrin Saturation</span> (%)</td>
<td class="Rrule" align="center">6.7</td>
<td class="Rrule" align="center">1.7</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Serum Ferritin (ng/dL)</td>
<td class="Rrule" align="center">73</td>
<td class="Rrule" align="center">-145</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<p class="First"><span class="Bold">Study C</span></p>
<p>Study C was a multicenter, randomized, open-label study of the safety and efficacy of two Ferrlecit dose regimens (1.5 mg/kg or 3.0 mg/kg of elemental iron) administered intravenously to 66 iron-deficient (<span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span> &lt; 20% and/or serum ferritin &lt; 100 ng/mL) pediatric hemodialysis patients, 6 to 15 years of age, inclusive who were receiving a stable erythropoietin dosing regimen. </p>
<p>Ferrlecit at a dose of 1.5 mg/kg or 3.0 mg/kg (up to a maximum dose of 125 mg of elemental iron) in 25 mL 0.9% sodium chloride was infused intravenously over 1 hour during each hemodialysis session for eight sequential dialysis sessions. Thirty-two patients received the 1.5 mg/kg dosing regimen (47% male, 53% female; 66% Caucasian, 25% Hispanic, and 3% Black, Asian, or Other; mean age 12.3 years). Thirty-four patients received the 3.0 mg/kg dosing regimen (56% male, 44% female; 77% Caucasian, 12% Hispanic, 9% Black, and 3% Other; mean age 12.0 years). </p>
<p>The primary endpoint was the change in hemoglobin concentration from baseline to 2 weeks after last Ferrlecit administration. There was no significant difference between the treatment groups. Improvements in hematocrit, <span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">transferrin saturation</span>, serum ferritin, and reticulocyte hemoglobin concentrations compared to baseline values were observed 2 weeks after the last Ferrlecit infusion in both the 1.5 mg/kg and 3.0 mg/kg treatment groups (Table 3).</p>
<a name="table3"></a><table width="100%">
<caption><span>TABLE 3 Study C: Hemoglobin, Hematocrit, and Iron Status</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left" colspan="2">Mean Change From Baseline to Two Weeks After Cessation of Therapy in Patients Completing Treatment</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule Toprule" align="center">1.5 mg/kg Ferrlecit<br> (N=25)</th>
<th class="Rrule Toprule" align="center">3.0 mg/kg Ferrlecit<br> (N=32)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Hemoglobin (g/dL)</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hematocrit (%)</td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">3.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306252" conceptname="Transferrin saturation">Transferrin Saturation</span> (%)</td>
<td class="Rrule" align="center">5.5</td>
<td class="Rrule" align="center">10.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Ferritin (ng/mL)</td>
<td class="Rrule" align="center">192</td>
<td class="Rrule" align="center">314</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Reticulocyte Hemoglobin Content (pg)</td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">1.2</td>
</tr>
</tbody>
</table>
<p>The increased hemoglobin concentrations were maintained at 4 weeks after the last Ferrlecit infusion in both the 1.5 mg/kg and the 3.0 mg/kg Ferrlecit dose treatment groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">How Supplied</span></p>
<p>NDC 0024-2794-10 for vials</p>
<p>Ferrlecit is supplied in colorless glass vials. Each sterile, single-use vial contains 62.5 mg of elemental iron in 5 mL for intravenous use, packaged in cartons of 10 vials. </p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.2"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 20 – 25°C (68 – 77°F); excursions permitted to 15 – 30°C (59 – 86°F). See USP Controlled Room Temperature. Do not freeze.</p>
<p><span class="Bold">Keep out of the reach of children.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Prior to Ferrlecit administration:</p>
<ul>
<li>Question patients regarding any prior history of reactions to parenteral iron products.</li>
<li>Advise patients of the risks associated with Ferrlecit.</li>
<li>Advise patients to report adverse reactions associated with the use of Ferrlecit, including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>,  light-headedness, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and breathing problems [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.2">5.2)</a></span> and <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1</a>, <a href="#S6.2">6.2)</a></span>]. </li>
</ul>
<p>Advise patients that Ferrlecit may reduce the absorption of concomitantly administered oral iron preparations [see <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>PREMIERPro™Rx is a trademark of Premier, Inc., used under license.</p>
<p>January 2014 </p>
<p>©2014 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton</h1>
<p class="First">NDC 0024-2794-10<br><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">Ferrlecit<span class="Sup">®</span></span></p>
<p><span class="Italics">sodium ferric gluconate<br>complex in sucrose injection</span></p>
<p><span class="Bold">62.5</span> mg elemental iron/<br><span class="Bold">5</span> mL Sterile Single-use <span class="Bold">Vial</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE ONLY</span></p>
<p><span class="Bold">10 x 5</span> mL Single Use Vials</p>
<p><span class="Bold">PREMIER</span>Pro™ Rx</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b25b34ab-9cf1-4a2b-bdf2-5eaf66625999&amp;name=ferrlecit-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FERRLECIT 		
					</strong><br><span class="contentTableReg">sodium ferric gluconate complex injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-2794</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sodium ferric gluconate complex</strong> (ferric cation) </td>
<td class="formItem">ferric cation</td>
<td class="formItem">12.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">195 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-2794-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020955</td>
<td class="formItem">07/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi-Aventis S.p.A.</td>
<td class="formItem"></td>
<td class="formItem">338454274</td>
<td class="formItem">MANUFACTURE(0024-2794), ANALYSIS(0024-2794), LABEL(0024-2794), PACK(0024-2794)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>586f2e14-e9ca-4669-ad40-54ec070ec78e</div>
<div>Set id: b25b34ab-9cf1-4a2b-bdf2-5eaf66625999</div>
<div>Version: 1</div>
<div>Effective Time: 20140523</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
